Ako-gun, Japan

Masaki Yamamoto


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masaki Yamamoto: Innovator in Prostaglandin Research

Introduction

Masaki Yamamoto is a distinguished inventor based in Ako-gun, Japan. He has made significant contributions to the field of biochemistry, particularly in the study of prostaglandins. His innovative work has led to advancements in the design of therapeutic agents for various medical conditions.

Latest Patents

Yamamoto holds a patent for a groundbreaking invention titled "Three-dimensional structure of prostaglandin D synthase and utilization thereof." This patent outlines a method for designing an anti-allergic agent, a sleep-controlling agent, an anti-obesity agent, and a remedy for brain injury. The invention acts via the inhibition of biosynthesis of prostaglandin D. The patent details the preparation of a crystal complex of human origin hematopoietic prostaglandin D synthase, glutathione, and a substrate analog or an inhibitor. The three-dimensional structural coordinates of each atom in the complex are determined through X-ray crystal analysis. He has 1 patent to his name.

Career Highlights

Masaki Yamamoto is affiliated with the Japan Science and Technology Agency, where he continues to conduct research and develop innovative solutions in his field. His work has garnered attention for its potential applications in medicine and pharmacology.

Collaborations

Yamamoto has collaborated with notable scientists, including Yoshihiro Urade and Osamu Hayaishi. These partnerships have further enriched his research and contributed to the advancement of knowledge in prostaglandin studies.

Conclusion

Masaki Yamamoto's contributions to the field of prostaglandin research exemplify the impact of innovation in medicine. His work not only enhances our understanding of biochemical processes but also paves the way for the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…